Placebo News and Research

RSS

Results of research study on the expression of KIF6 in mouse model

Celera Corporation and its collaborators at The University of Washington, WA, and Indiana University, IN, today announced the presentation of data from a research study that investigated the expression of KIF6 in a mouse Celera Corporation model. A key finding was that KIF6 was specifically expressed in macrophages and chondrocytes in mouse atherosclerotic lesions, but not in normal arteries.

12 Apr 2010

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

Oceana Therapeutics and Q-Med AB today announced the filing of a Premarket Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for Solesta® for the treatment of Fecal (or Bowel) Incontinence, a largely unsatisfied medical need afflicting millions of Americans.

12 Apr 2010

Worsening suicidality thoughts while on antidepressants linked to specific changes in brain function

While antidepressant medications have proven to be beneficial in helping people overcome major depression, it has long been known that a small subset of individuals taking these drugs can actually experience a worsening of mood, and even thoughts of suicide. No clinical test currently exists to make this determination, and only time - usually weeks - can tell before a psychiatrist knows whether a patient is getting better or worse.

12 Apr 2010

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

The antiepileptic drug Vimpat- (lacosamide) (C-V) will be the subject of numerous studies and analyses-both UCB-sponsored and independent-at the 62nd annual American Academy of Neurology meeting, taking place at the Metro Toronto Convention Centre in Toronto from April 10-17.

9 Apr 2010

Catalyst Pharmaceutical Partners' vigabatrin data to be presented at 41st ASAM conference

Catalyst Pharmaceutical Partners, Inc. today announced that on Friday April 16th, Eugene C. Somoza, MD, PhD, University of Cincinnati College of Medicine and VA Medical Center, Cincinnati, OH will present a paper he authored along with Charles Gorodetzky, MD, PhD, Douglas Winship and Peggy Somoza, entitled: "A Multi-Site, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Vigabatrin (VGB) for Treating Cocaine Dependence"

9 Apr 2010

Tβ4 therapy for ocular disorders closer to reality

RegeneRx Biopharmaceuticals, Inc. announced today that Tβ4, a synthetic version of a naturally occurring peptide that is the basis for the company's product candidates, will be the subject of three poster presentations at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to be held in Fort Lauderdale, Florida from May 2-6, 2010.

9 Apr 2010

World's largest autism science and advocacy organization awards 16 new research grants

Autism Speaks, the world's largest autism science and advocacy organization, today announced the awarding of 16 new research grants totaling $5,223,743 over the next three years.

9 Apr 2010

Omega-3 fatty acids improve nerve regeneration, prevent psychotic disorders and reduce cellular aging

Improving nerve regeneration after corneal surgery, preventing psychotic disorders in those at high risk for them and reducing cellular aging are three emerging benefits of the omega-3 fatty acids found in seafood, according to milestone research described in the April 2010 PUFA Newsletter and Fats of Life online publications for health professionals and consumers, respectively.

9 Apr 2010

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Keryx Biopharmaceuticals, Inc. announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of patients with refractory advanced colorectal cancer.

9 Apr 2010

University of Southampton, Synairgen Research scientists commence Phase II trial of interferon beta for asthma

Scientists from the University of Southampton and Synairgen Research Ltd, a respiratory drug development company spun out from the University, have begun a Phase II study into the effectiveness of the drug interferon beta for asthma patients.

9 Apr 2010

Study shows benefits of oxytocin nasal spray in children with ASD

Autism spectrum disorders are developmental disorders usually diagnosed in childhood. Children with ASDs have impairments in social interactions and communication, and a tendency towards repetitive behaviors. A hallmark of autism is a difficulty in understanding and reciprocating the emotion of others.

8 Apr 2010

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of a phase III clinical trial of brentuximab vedotin (SGN-35) for post-transplant Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, which is expressed on malignant Hodgkin lymphoma cells.

8 Apr 2010

Dutasteride may help reduce risk of developing prostate cancer, say researchers

A drug already used to shrink benign, enlarged prostates could also help to reduce the risk of developing prostate cancer, according to researchers in the US.

8 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.

8 Apr 2010

MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE

MAP Pharmaceuticals, Inc. today announced that the Company initiated a pharmacodynamics (PD) trial to compare the acute effect of LEVADEX™ orally inhaled migraine therapy to intravenous dihydroergotamine mesylate (IV DHE) and placebo on pulmonary artery pressure as measured by echocardiography.

8 Apr 2010

King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain

DURECT Corporation announced today that its licensee, King Pharmaceuticals, has begun a Phase IIb clinical trial to evaluate ELADUR™ (TRANSDUR™-Bupivacaine) for the treatment of chronic low back pain. ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application.

7 Apr 2010

HRV devices reduce respiratory symptoms in children: Study

Houses today are so well sealed that they can trap humidity and pollutants indoors as a result of insufficient ventilation. Recently, a team of Canadian scientists led by Dr. Tom Kovesi, a pediatric respirologist at the Children's Hospital of Eastern Ontario in Ottawa, Canada, performed a randomized double-blind, placebo controlled trial to determine whether use of heat recovery ventilators would increase home ventilation and therefore reduce the risk of lower respiratory tract illness in young children.

7 Apr 2010

Researchers commence Phase 2 research study to test CERE-110 for AD

Researchers at Banner Sun Health Research Institute are about to start the first Phase 2 research study to test a gene transfer agent for Alzheimer's disease. AD is a degenerative and ultimately fatal disorder affecting as many as five million Americans and that number is expected to soar to more than 11 million by 2040.

7 Apr 2010

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Genta Incorporated today announced that the U.S. Food and Drug Administration (FDA) has granted the Company's request for "Fast Track" designation of tesetaxel for treatment of patients with advanced gastric cancer. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

7 Apr 2010

Placebo News and Research

Results of research study on the expression of KIF6 in mouse model

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

Worsening suicidality thoughts while on antidepressants linked to specific changes in brain function

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

Catalyst Pharmaceutical Partners' vigabatrin data to be presented at 41st ASAM conference

Tβ4 therapy for ocular disorders closer to reality

World's largest autism science and advocacy organization awards 16 new research grants

Omega-3 fatty acids improve nerve regeneration, prevent psychotic disorders and reduce cellular aging

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

University of Southampton, Synairgen Research scientists commence Phase II trial of interferon beta for asthma

Study shows benefits of oxytocin nasal spray in children with ASD

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

Dutasteride may help reduce risk of developing prostate cancer, say researchers

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE

King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain

HRV devices reduce respiratory symptoms in children: Study

Researchers commence Phase 2 research study to test CERE-110 for AD

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News